Moleculin Biotech, Inc.
MBRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001659617
In the last 90 days, Moleculin Biotech, Inc. insiders filed 3 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $518.5K in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Moleculin Biotech, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 32 | 1 | 24 | −7 |
| Shares | 2.98M | 334 | 2.86M | −122.2K (−4.1%) |
| Value | $10.9M | $1.00K | $8.57M | −$2.36M (−21.6%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Moleculin Biotech, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Charles Schwab Investment Management Inc | 20,198 | $61.0K | 0.00% |
| Migdal Insurance & Financial Holdings Ltd. | 2,284 | $7.00K | 0.00% |
Sold out (9)
Institutions that held Moleculin Biotech, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Citadel Advisors LLC | 38,053 | $140.0K |
| XTX Topco Ltd | 32,997 | $121.0K |
| Gsa Capital Partners LLP | 31,120 | $114.0K |
| Goldman Sachs Group Inc | 25,707 | $94.0K |
| Virtu Financial LLC | 25,302 | $93.0K |
| Taylor, Cottrill, Erickson & Associates, Inc. | 16,964 | $62.0K |
| CVA Family Office, LLC | 500 | $2.00K |
| Salem Investment Counselors Inc | 5 | $0 |
| Strategic Blueprint, LLC | 90 | $0 |
Not filed for Q3 2021 yet (1)
Institutions that held Moleculin Biotech, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| CWM, LLC | 334 | $1.00K |